Zai Lab Ltd ADR Repr 1 Shs ZLAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
-
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
-
Zai Lab Announces Changes to Senior Leadership Team
-
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
-
Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
-
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
-
Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
-
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas
Trading Information
- Previous Close Price
- $19.98
- Day Range
- $19.90–20.90
- 52-Week Range
- $15.96–41.20
- Bid/Ask
- $20.00 / $20.88
- Shares Outstanding
- 112.92M
- Market Cap
- $2.31B
- Volume/Avg
- 1M / 895,604
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.70
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 1,784
- Website
- https://www.zailaboratory.com
Valuation
|
Metric
|
ZLAB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.24 |
Price/Sales | 4.70 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ZLAB
|
|---|---|
Quick Ratio | 1.84 |
Current Ratio | 2.40 |
Interest Coverage | −36.19 |
Quick Ratio
ZLAB
Profitability
|
Metric
|
ZLAB
|
|---|---|
Return on Assets (Normalized) | −11.79% |
Return on Equity (Normalized) | −18.17% |
Return on Invested Capital (Normalized) | −16.77% |
Return on Assets
ZLAB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>&<!w# | LOCK|!tmf | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$!bz!p | LOCK|#xnC? | $70B | |||
| argenx SE ADR
ARGX
| LOCK|cKQn%@ | LOCK|zZ@ | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|SpVpRWW | LOCK|z#DDY | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Yl?HWh% | LOCK|bw | $36B | |||
| Moderna Inc
MRNA
| LOCK|FQ@YM$ | LOCK|gy | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#t@#?HY$ | LOCK|<m>n | $25B | |||
| Incyte Corp
INCY
| LOCK|^qyR^p% | LOCK|Q^ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|l?LJXz | LOCK|cZ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|cS@xLW# | LOCK|<RM | $17B |
United States